Protective effects of inhaled carbon monoxide in endotoxin-induced cholestasis is dependent on its kinetics
Language English Country France Media print-electronic
Document type Journal Article, Research Support, Non-U.S. Gov't
PubMed
24148277
DOI
10.1016/j.biochi.2013.10.009
PII: S0300-9084(13)00358-1
Knihovny.cz E-resources
- Keywords
- Carbon monoxide, Cholestasis, Endotoxin, Heme oxygenase,
- MeSH
- Cholestasis chemically induced drug therapy metabolism pathology MeSH
- Gene Expression MeSH
- Heme Oxygenase (Decyclizing) genetics metabolism MeSH
- Interleukin-10 genetics metabolism MeSH
- Interleukin-6 genetics metabolism MeSH
- Liver drug effects metabolism pathology MeSH
- Rats MeSH
- Lipopolysaccharides MeSH
- RNA, Messenger genetics metabolism MeSH
- Carbon Monoxide pharmacokinetics pharmacology MeSH
- Half-Life MeSH
- Rats, Wistar MeSH
- Tumor Necrosis Factor-alpha genetics metabolism MeSH
- Carrier Proteins genetics metabolism MeSH
- Bile chemistry MeSH
- Bile Ducts drug effects metabolism pathology MeSH
- Animals MeSH
- Check Tag
- Rats MeSH
- Female MeSH
- Animals MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Names of Substances
- Heme Oxygenase (Decyclizing) MeSH
- Hmox1 protein, rat MeSH Browser
- Interleukin-10 MeSH
- Interleukin-6 MeSH
- Lipopolysaccharides MeSH
- RNA, Messenger MeSH
- Carbon Monoxide MeSH
- Tumor Necrosis Factor-alpha MeSH
- Carrier Proteins MeSH
Carbon monoxide (CO), a product of heme oxygenase (HMOX), has many beneficial biological functions and is a promising therapeutic agent for many pathological conditions. However, the kinetics of inhaled CO and its protective role in endotoxin-induced cholestasis is not fully known. Thus, our objective was to characterize the kinetics of inhaled CO and then investigate its use in early phase experimental endotoxin-induced cholestasis. Female Wistar rats were randomly divided into 4 groups: CON (control), LPS (lipopolysaccharide, 6 mg/kg), CO (250 ppm COx1h), and CO + LPS. Rats were sacrificed at 0-12 h after LPS administration. Tissues and blood were collected for liver injury markers and tissue CO distribution measurements. Livers were harvested for measurements of Hmox activity, Hmox1 mRNA expression, cytokines (IL10, IL6, TNF), and bile lipid and pigment transporters. Half-lives of CO in spleen, blood, heart, brain, kidney, liver, and lungs were 2.4 ± 1.5, 2.3 ± 0.8, 1.8 ± 1.6, 1.5 ± 1.2, 1.1 ± 1.1, 0.6 ± 0.3, 0.6 ± 0.2 h, respectively. CO treatment increased liver IL10 mRNA and decreased TNF expression 1 h after LPS treatment and prevented the down-regulation of bile acid and bilirubin hepatic transporters (Slc10a1, Abcb11, and Abcc2, p < 0.05), an effect closely related to the kinetics. The protective effect of CO against cholestatic liver injury persisted even 12 h after CO exposure, as shown by attenuation of serum cholestatic markers in CO-treated animals. CO exposure substantially attenuated endotoxin-induced cholestatic liver injury and was directly related to the kinetics of inhaled CO. This data underscores the importance of the kinetics of inhaled CO for the proper design of experimental and clinical studies of using CO as a treatment strategy.
Department of Pediatrics Stanford University School of Medicine Stanford CA USA
Institute of Pharmacology 1st Faculty of Medicine Charles University Prague Prague Czech Republic
References provided by Crossref.org
Carbon Monoxide-Releasing Activity of Plant Flavonoids
Protective effect of heme oxygenase induction in ethinylestradiol-induced cholestasis
